Daré Bioscience
Biotechnology, 3655 Nobel Dr Ste 260, San Diego, California, 92122, United States, 1-10 Employees
Phone Number: 85********
Who is DARÉ BIOSCIENCE
Dare Bioscience (NASDAQ: DARE) is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women's health. With eight potentially first-in-class ...
Read More
-
Headquarters: 3655 Nobel Dr Ste 260, San Diego, California, 92122, United States
-
Date Founded: 2015
-
Employees: 1-10
-
Revenue: $1 Million to $5 Million
-
Active Tech Stack: See technologies
-
CEO:
Sabrina Johnson
Email
Phone
Industry: Biotechnology
SIC Code: 2834
Does something look wrong? Fix it. | View contact records from DARÉ BIOSCIENCE
Daré Bioscience Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Daré Bioscience
Answer: Daré Bioscience's headquarters are located at 3655 Nobel Dr Ste 260, San Diego, California, 92122, United States
Answer: Daré Bioscience's phone number is 85********
Answer: Daré Bioscience's official website is https://darebioscience.com
Answer: Daré Bioscience's revenue is $1 Million to $5 Million
Answer: Daré Bioscience's SIC: 2834
Answer: Daré Bioscience has 1-10 employees
Answer: Daré Bioscience is in Biotechnology
Answer: Daré Bioscience contact info: Phone number: 85******** Website: https://darebioscience.com
Answer: Dare Bioscience (NASDAQ: DARE) is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women's health. With eight potentially first-in-class womens health products in development, we are committed to bring to market differentiated products designed to expand treatment options, improve outcomes, and facilitate a better quality of life for women. Vaginal drug delivery is often the optimum delivery approach to achieve these objectives, and IVR technology has become one of our preferred investigational platforms. Our portfolio features innovative IVR technologies including our non-hormonal contraceptive Ovaprene, which we believe has the potential to disrupt the contraceptive landscape by providing protection for one month, without the use hormones, and our suite of ethylene-vinyl acetate (EVA) matrixed IVRs that can provide flexibility in terms of drug loading, drug delivery, and modulation of release rates across a wide array of molecules, hormones, peptides and proteins, facilitating new indications and applications of the technology. Dares EVA IVR technology includes DARE-HRT1 for dual hormone replacement as a potential treatment for the vasomotor symptoms of menopause and DARE-FRT1 for vaginal progesterone delivery in support of fertility and the prevention of pre-term birth. In addition to its novel IVR technologies, Dare is developing a topical formulation of sildenafil, the active ingredient in the blockbuster product Viagra, for the treatment of female sexual arousal disorder (FSAD) as well as a novel vaginal formulation of the selective estrogen receptor modulator (SERM) tamoxifen to address and alleviate the symptoms of vulvar vaginal atrophy (VVA) for women diagnosed with and treated for hormone-receptor-positive (HR+) breast cancer.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month